NCT05434156View on ClinicalTrials.gov

ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

October 27, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Healthy VolunteersMajor Depressive DisorderDepression
Interventions
DRUG

ELE-101

ELE-101 solution for intravenous infusion

DRUG

ELE-101 Placebo

ELE-101 placebo matching solution for intravenous infusion

Trial Locations (2)

L34 1BH

MAC Clinical Research, Liverpool

M13 9NQ

MAC Clinical Research, Manchester

Sponsors

Collaborators (1)

Beckley Psytech Limited
All Listed Sponsors
collaborator

Beckley Psytech Limited

INDUSTRY

lead

Eleusis Therapeutics

INDUSTRY

NCT05434156 - ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression | Biotech Hunter | Biotech Hunter